Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- HIV life cycle
- The HIV-1 genome
- Synthesis of HIV-1 envelope glycoproteins
- HIV life cycle: targets for antiretroviral therapy
- Mechanism of HIV-1 entry
- HIV-1 binding inhibitors
- Polyanions as inhibitors of HIV attachment
- Small-molecule inhibitors of CD4-gp120 interaction
- HIV-1 coreceptor inhibitors
- Coreceptor usage of HIV-1 variants
- Viral composition of pure/mixed populations
- CXCR4 antagonists with potent anti-HIV activity
- Drugs blocking gp120 - CCR5 interaction
- Maraviroc
- Activity of maraviroc
- MOTIVATE 1 and 2 clinical trials
- Coreceptor tropism by treatment status
- Resistance in the absence of coreceptors
- Second generation HIV entry inhibitors
- HIV-1 fusion inhibitors
- Mechanism of gp41 dependant fusion
- Fusion inhibitors: enfuvirtide (T20)
- TORO trials
- Predictors of virological response
- Limitations for the use of enfuvirtide
- Resistance to enfuvirtide
- Second generation fusion inhibitors
- The discovery of virus-inhibitory peptide (virip)
- Pilot phase I/II clinical trial of vir576
- Future perspectives for HIV entry
- Future perspectives for HIV entry: gene therapy
- New strategies to prevent HIV infection
- Hematopoietic cells targeted to CCR5
- Conclusions
Topics Covered
- HIV life cycle
- The HIV-1 genome
- Synthesis of HIV-1 envelope glycoproteins
- Targets for antiretroviral therapy
- Mechanism of HIV-1 entry
- HIV entry inhibition
- HIV-1 binding inhibitors
- HIV-1 coreceptor inhibitors
- Viral composition of pure/mixed populations
- CXCR4 antagonists
- Drugs blocking gp120-CCR5 interaction
- Maraviroc
- MOTIVATE 1 and 2 clinical trials
- Coreceptor tropism by treatment status
- Resistance in the absence of coreceptors
- HIV-1 fusion inhibitors
- TORO trials
- Predictors of virological response
- The virus-inhibitory peptide (virip)
- New strategies to prevent HIV infection
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Esté, J. (2011, August 30). HIV entry inhibitors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/RYTI5236.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. José Esté has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.